Vancomycin-intermediate resistance in Staphylococcus aureus

Journal of Global Antimicrobial Resistance

Volumn 2, Issue 4, 2014, Pages 213-224

  Hiramatsu, Keiichi ^a   Kayayama, Yuki ^a   Matsuo, Miki ^a   Aiba, Yoshifumi ^a   Saito, Michie ^a   Hishinuma, Tomomi ^a   Iwamoto, Akira ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

hVISA; Pre hVISA; rpoB mutation; sVISA; Vancomycin; VISA

Indexed keywords

PEPTIDOGLYCAN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; CELL MEMBRANE; CELL POPULATION; CELL WALL; CHROMOSOME MUTATION; CLINICAL FEATURE; DENSITOMETRY; GENE EXPRESSION; GRAM NEGATIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MICROARRAY ANALYSIS; NONHUMAN; OUTER MEMBRANE; PHENOTYPE; PLEIOTROPY; REGULATOR GENE; REVIEW; STAPHYLOCOCCUS AUREUS; TRANSMISSION ELECTRON MICROSCOPY; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS AUREUS;

EID: 84916607774     PISSN: 22137165     EISSN: 22137173     Source Type: Journal    
DOI: 10.1016/j.jgar.2014.04.006     Document Type: Review

References (64)

1. K. Hiramatsu, H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F.C. Tenover Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J Antimicrob Chemother 40 1997 135 136
2. K. Hiramatsu, N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, and S. Hori Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin Lancet 350 1997 1670 1673
3. K. Hiramatsu Vancomycin resistance in staphylococci Drug Resist Updat 1 1998 135 150
4. F.C. Tenover, and R.C. Moellering Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus Clin Infect Dis 44 2007 1208 1215
5. S. Chang, D.M. Sievert, J.C. Hageman, M.L. Boulton, F.C. Tenover, and F.P. Downes Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene N Engl J Med 348 2003 1342 1347
6. W.A. Craig, and D.R. Andes In vivo pharmacodynamics of vancomycin against VISA, heteroresistant VISA (hVISA) and VSSA in the neutropenic murine thigh-infection model 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 27-30 September 2006, San Francisco, CA 2006 American Society for Microbiology Washington, DC 16 [abstract A644]
7. P.E. Reynolds Structure, biochemistry and mechanism of action of glycopeptide antibiotics Eur J Clin Microbiol Infect Dis 11 1989 943 950
8. K. Hiramatsu Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance Lancet Infect Dis 1 2001 147 155
9. L. Cui, A. Iwamoto, J.Q. Lian, H.M. Neoh, T. Maruyama, and Y. Horikawa Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus Antimicrob Agents Chemother 50 2006 428 438
10. H. Hanaki, and K. Hiramatsu Detection methods of glycopeptide-resistant Staphylococcus aureus I: susceptibility testing S.H. Gillespie, Antibiotic resistance: methods and protocols. Methods in molecular medicine vol. 48 1998 Humana Press Inc. Totowa, NJ 85 91
11. K. Hiramatsu The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan Am J Med 104 1998 7S 10S
12. K. Hiramatsu, and H. Hanaki Glycopeptide resistance in staphylococci Curr Opin Infect Dis 11 1998 653 658
13. L. Cui, X. Ma, K. Sato, K. Okuma, F.C. Tenover, and E.M. Mamizuka Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus J Clin Microbiol 41 2003 5 14
14. H. Hanaki, K. KuwaharaArai, S. BoyleVavra, R.S. Daum, H. Labischinski, and K. Hiramatsu Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50 J Antimicrob Chemother 42 1998 199 209
15. H. Hanaki, H. Labischinski, Y. Inaba, N. Kondo, H. Murakami, and K. Hiramatsu Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50 J Antimicrob Chemother 42 1998 315 320
16. L. Cui, H. Murakami, K. Kuwahara-Arai, H. Hanaki, and K. Hiramatsu Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50 Antimicrob Agents Chemother 44 2000 2276 2285
17. A.M. Stranden, M. Roos, and B. Berger-Bachi Glutamine synthetase and heteroresistance in methicillin-resistant Staphylococcus aureus Microb Drug Resist 2 1996 201 207
18. M. Kuroda, T. Ohta, I. Uchiyama, T. Baba, H. Yuzawa, and I. Kobayashi Whole genome sequencing of methicillin-resistant Staphylococcus aureus Lancet 357 2001 1225 1240
19. M. Kuroda, K. Kuwahara-Arai, and K. Hiramatsu Identification of the up and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method Biochem Biophys Res Commun 269 2000 485 490
20. M. Kuroda, H. Kuroda, T. Oshima, F. Takeuchi, H. Mori, and K. Hiramatsu Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus Mol Microbiol 49 2003 807 821
21. Y. Katayama, H. Murakami-Kuroda, L. Cui, and K. Hiramatsu Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem Antimicrob Agents Chemother 53 2009 3190 3196
22. J. Yamakawa, M. Aminaka, K. Okuzumi, H. Kobayashi, Y. Katayama, and S. Kondo Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study J Infect Chemother 18 2012 406 409
23. Y. Kato, T. Suzuki, T. Ida, and K. Maebashi Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR J Antimicrob Chemother 65 2010 37 45
24. Y. Kato, T. Suzuki, T. Ida, K. Maebashi, M. Sakurai, and J. Shiotani Microbiological and clinical study of methicillin-resistant Staphylococcus aureus (MRSA) carrying VraS mutation: changes in susceptibility to glycopeptides and clinical significance Int J Antimicrob Agents 31 2008 64 70
25. S. Boyle-Vavra, S. Yin, D.S. Jo, C.P. Montgomery, and R.S. Daum VraT/YvqF is required for methicillin resistance and activation of the VraSR regulon in Staphylococcus aureus Antimicrob Agents Chemother 57 2013 83 95
26. S. Gardete, C. Kim, B.M. Hartmann, M. Mwangi, C.M. Roux, and P.M. Dunman Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300 PLoS Pathog 8 2012 e1002505
27. T. Tanaka, K. Okuzumi, A. Iwamoto, and K. Hiramatsu A retrospective study on methicillin-resistant Staphylococcus aureus clinical strains in Tokyo University Hospital J Infect Chemother 1 1995 42 51
28. A. Jansen, M. Türck, C. Szekat, M. Nagel, I. Clever, and G. Bierbaum Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus Int J Med Microbiol 297 2007 205 215
29. M. Shoji, L. Cui, R. Iizuka, A. Komoto, H.M. Neoh, and Y. Watanabe walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus Antimicrob Agents Chemother 55 2011 3870 3881
30. B.P. Howden, C.R. McEvoy, D.L. Allen, K. Chua, W. Gao, and P.F. Harrison Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR PLoS Pathog 7 2011 e1002359
31. P. Bisicchia, D. Noone, E. Lioliou, A. Howell, S. Quigley, and T. Jensen The essential YycFG two-component system controls cell wall metabolism in Bacillus subtilis Mol Microbiol 65 2007 180 200
32. H.M. Neoh, L. Cui, H. Yuzawa, F. Takeuchi, M. Matsuo, and K. Hiramatsu Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance Antimicrob Agents Chemother 52 2008 45 53
33. B.P. Howden, T.P. Stinear, D.L. Allen, P.D. Johnson, P.B. Ward, and J.K. Davies Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus Antimicrob Agents Chemother 52 2008 3755 3762
34. M. Matsuo, T. Hishinuma, Y. Katayama, L. Cui, M. Kapi, and K. Hiramatsu Mutation of RNA polymerase β subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3 Antimicrob Agents Chemother 55 2011 4188 4195
35. A. Peschel, R.W. Jack, M. Otto, L.V. Collins, P. Staubitz, and G. Nicholson Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine J Exp Med 193 2001 1067 1076
36. M. Falord, G. Karimova, A. Hiron, and T. Msadek GraXSR proteins interact with the VraFG ABC transporter to form a five-component system required for cationic antimicrobial peptide sensing and resistance in Staphylococcus aureus Antimicrob Agents Chemother 56 2012 1047 1058
37. M. Saito, Y. Katayama, T. Hishinuma, A. Iwamoto, Y. Aiba, and K. Kuwahara-Arai 'Slow VISA' (sVISA), a novel phenotype of vancomycin resistance, obtained in vitro from hVISA strain Mu3 Antimicrob Agents Chemother 2014 [Epub ahead of print]
38. M. Matsuo, L. Cui, J. Kim, and K. Hiramatsu Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3 Antimicrob Agents Chemother 57 2013 5843 5853
39. Y. Watanabe, L. Cui, Y. Katayama, K. Kishii, and K. Hiramatsu Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus J Clin Microbiol 49 2011 2680 2684
40. L. Cui, E. Tominaga, H.M. Neoh, and K. Hiramatsu Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus Antimicrob Agents Chemother 50 2006 1079 1082
41. I.L. Camargo, H.M. Neoh, L. Cui, and K. Hiramatsu Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype Antimicrob Agents Chemother 52 2008 4289 4299
42. I.M. Gould Treatment of bacteraemia: methicillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA) Int J Antimicrob Agents 42 Suppl. 2013 S17 S21
43. L. Cui, J.Q. Lian, H.M. Neoh, E. Reyes, and K. Hiramatsu DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus Antimicrob Agents Chemother 49 2005 3404 3413
44. Y. Kawai, J. Marles-Wright, R.M. Cleverley, R. Emmins, S. Ishikawa, and M. Kuwano A widespread family of bacterial cell wall assembly proteins EMBO J 30 2011 4931 4941
45. Y.G. Chan, M.B. Frankel, V. Dengler, O. Schneewind, and D. Missiakas Staphylococcus aureus mutants lacking the LytR-CpsA-Psr family of enzymes release cell wall teichoic acids into the extracellular medium J Bacteriol 195 2013 4650 4659
46. R. Biswas, R.E. Martinez, N. Göhring, M. Schlag, M. Josten, and G. Xia Proton-binding capacity of Staphylococcus aureus wall teichoic acid and its role in controlling autolysin activity PLoS ONE 7 2012 e41415
47. Centers for Disease Control and Prevention (CDC) Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997 MMWR Morb Mortal Wkly Rep 46 1997 813 815
48. M. Kapi, F. Takeuchi, K. Okuma, M. Kuroda, L. Cui, and K. Yamamoto Spontaneous mutation accompanying decreased growth rate and cell wall thickening confers vancomycin resistance in the subpopulation of heterogeneously vancomycin-resistant strain Mu3 Juntendo Med J 51 2005 352 360 [in Japanese]
49. F. Schaaff, A. Reipert, and G. Bierbaum An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus Antimicrob Agents Chemother 46 2002 3540 3548
50. K.D. Passalacqua, S.W. Satola, E.K. Crispell, and T.D. Read A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin Antimicrob Agents Chemother 56 2012 5212 5223
51. J.E. Finan, G.L. Archer, M.J. Pucci, and M.W. Climo Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 45 2001 3070 3075
52. L. Cui, T. Isii, M. Fukuda, T. Ochiai, H.M. Neoh, and I.L. Camargo An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus Antimicrob Agents Chemother 54 2010 5222 5233
53. M.M. Mwangi, S.W. Wu, Y. Zhou, K. Sieradzki, H. de Lencastre, and P. Richardson Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing Proc Natl Acad Sci U S A 104 2007 9451 9456
54. C.R. McEvoy, B. Tsuji, W. Gao, T. Seemann, J.L. Porter, and K. Doig Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression Antimicrob Agents Chemother 57 2013 3240 3249
55. S. Dubrac, I.G. Boneca, O. Poupel, and T. Msadek New insights into the WalK/WalR (YycG/YycF) essential signal transduction pathway reveal a major role in controlling cell wall metabolism and biofilm formation in Staphylococcus aureus J Bacteriol 189 2007 8257 8269
56. J. Baddiley, N.L. Blumsom, and L.J. Douglas The biosynthesis of the wall teichoic acid in Staphylococcus lactis I3 Biochem J 110 1968 565 571
57. K. Yokoyama, H. Mizuguchi, Y. Araki, S. Kaya, and E. Ito Biosynthesis of linkage units for teichoic acids in Gram-positive bacteria: distribution of related enzymes and their specificities for UDP-sugars and lipid-linked intermediates J Bacteriol 171 1989 940 946
58. M.A. D'Elia, M.P. Pereira, Y.S. Chung, W. Zhao, A. Chau, and T.J. Kenney Lesions in teichoic acid biosynthesis in Staphylococcus aureus lead to a lethal gain of function in the otherwise dispensable pathway J Bacteriol 188 2006 4183 4189
59. N. Kondo, K. Kuwahara-Arai, H. Kuroda-Murakami, E. Tateda-Suzuki, and K. Hiramatsu Eagle-type methicillin resistance: new phenotype of high methicillin resistance under mec regulator gene control Antimicrob Agents Chemother 45 2001 815 824
60. Y. Watanabe, H.M. Neoh, L. Cui, and K. Hiramatsu Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus Antimicrob Agents Chemother 52 11 2008 4207 4208
61. Y. Aiba, Y. Katayama, T. Hishinuma, H. Murakami-Kuroda, L. Cui, and K. Hiramatsu Mutation of RNA polymerase β-subunit gene promotes heterogeneous-to-homogeneous conversion of β-lactam resistance in methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 57 2013 4861 4871
62. J. Bartley First case of VRSA identified in Michigan Infect Control Hosp Epidemiol 23 2002 480
63. K. Hiramatsu, L. Cui, and K. Kuwahara-Arai Has vancomycin-resistant Staphylococcus aureus started going it alone? Lancet 364 2004 565 566
64. K. Hiramatsu, T. Ito, S. Tsubakishita, T. Sasaki, F. Takeuchi, and Y. Morimoto Genomic basis for methicillin resistance in Staphylococcus aureus Infect Chemother 45 2013 117 136